Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
Antidepressant Tolerability and Potential Clinical Implications of Serotonin-2A Receptor Genotypes
| James M Stevenson and Jeffrey R Bishop* | |
| Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, USA | |
| Corresponding Author : | Dr. Jeffrey R Bishop Department of Pharmacy Practice University of Illinois at Chicago College of Pharmacy 833 S. Wood St Rm 164 (M/C 886), Chicago, IL 60612, USA E-mail: jbishop@uic.edu |
| Received April 29, 2013; Accepted June 14, 2013; Published June 17, 2013 | |
| Citation: Stevenson JM, Bishop JR (2013) Antidepressant Tolerability and Potential Clinical Implications of Serotonin-2A Genotypes. Clin Pharmacol Biopharm 2:109. doi:10.4172/2167-065X.1000109 | |
| Copyright: © 2013 Stevenson JM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
Despite the development of new therapeutic agents for the treatment of mood disorders, drug tolerability remains a major barrier to effective treatment for many patients. Pharmacogenomic studies aim to identify genetic markers that moderate drug response and tolerability, with the intention that this information will aid in drug selection and dosing. The serotonin-2A receptor gene (HTR2A) is one attractive candidate gene for pharmacogenomic studies of drugs for mood disorders. Numerous studies have examined associations between polymorphisms within this gene and efficacy and tolerability of drugs for mood disorders. Some of these variants are now being included in some commercially-available platforms with the intent of using them for therapeutic decision making. As these technologies become more widely utilized, clinicians will face decision about what this information means for patients and how/if to apply this information clinically. This review aims to assist clinicians in this task by summarizing pharmacogenomic studies of the association between polymorphisms of HTR2A and tolerability outcomes in a number of adverse drug reaction domains.
